

October 13, 2026

News Release

Company: Olympus Corporation

Bob White, Director, Representative Executive Officer, President and CEO

(Code: 7733, Prime, Tokyo Stock Exchange)

Contact: Takaaki Sakurai, Vice President, Investor Relations

TEL: +81-42-642-2111

Notice Regarding Receipt of Warning Letter from FDA

Olympus Corporation ("Olympus") hereby announces that the Company received a Warning Letter from the United States Food and Drug Administration ("FDA") dated October 7, 2026 (U.S. time) following FDA inspections conducted at Olympus facilities in late 2025. The facilities that are addressed by the Warning Letter include: Olympus Medical Systems Corporation (Hachioji and Hinode, Japan), Aomori Olympus Co., Ltd. (Japan), Shirakawa Olympus Co., Ltd. (Japan), Olympus Winter & IBE GmbH (Hamburg, Germany) and Gyrus ACMI, Inc. (Brooklyn Park, U.S.).

The Warning Letter addresses the adequacy of Olympus' comprehensive responses to quality management system and process observations previously identified in Form 483s issued following late 2025 inspections of the six facilities listed above. Olympus has already implemented significant corrective and preventive actions that should substantively address the feedback set forth in the Warning Letter. Olympus is working closely with the FDA and will submit a response within 15 business days of receipt of the Warning Letter. Olympus remains committed to working with the FDA to address its feedback with patient safety as the top priority.

The Warning Letter does not restrict Olympus's ability to produce, market, manufacture or distribute products, require recall of any products, nor restrict Olympus' ability to seek FDA 510(k) clearance of new products.

Based on information currently available, Olympus does not anticipate that the Warning Letter will have an impact on its consolidated financial results. Should any material developments occur, Olympus will make appropriate disclosures in accordance with applicable laws and regulations.